A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
Status:
Active, not recruiting
Trial end date:
2022-10-27
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and
irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced
B-cell malignancies. This study is divided into 3 parts: Part 1 (dose-confirmation phase),
Part 2 (dose-expansion phase) and Part 3 (dose-confirmation phase for combination therapy).